CH672251A5 - - Google Patents
Download PDFInfo
- Publication number
- CH672251A5 CH672251A5 CH3458987A CH3458987A CH672251A5 CH 672251 A5 CH672251 A5 CH 672251A5 CH 3458987 A CH3458987 A CH 3458987A CH 3458987 A CH3458987 A CH 3458987A CH 672251 A5 CH672251 A5 CH 672251A5
- Authority
- CH
- Switzerland
- Prior art keywords
- medicament according
- rats
- dose
- introduction
- drug
- Prior art date
Links
- 239000003814 drug Substances 0.000 claims description 117
- 230000001076 estrogenic effect Effects 0.000 claims description 19
- 206010067572 Oestrogenic effect Diseases 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 33
- 229940079593 drug Drugs 0.000 description 31
- 230000000694 effects Effects 0.000 description 21
- 229940088597 hormone Drugs 0.000 description 20
- 239000005556 hormone Substances 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 18
- 230000035935 pregnancy Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 102000009151 Luteinizing Hormone Human genes 0.000 description 12
- 108010073521 Luteinizing Hormone Proteins 0.000 description 12
- 229940040129 luteinizing hormone Drugs 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000028327 secretion Effects 0.000 description 12
- 206010062767 Hypophysitis Diseases 0.000 description 11
- 235000013399 edible fruits Nutrition 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000003635 pituitary gland Anatomy 0.000 description 11
- 210000004291 uterus Anatomy 0.000 description 11
- 230000035800 maturation Effects 0.000 description 10
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 9
- 230000003325 follicular Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 229940126601 medicinal product Drugs 0.000 description 9
- 210000001672 ovary Anatomy 0.000 description 9
- 230000026234 pro-estrus Effects 0.000 description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 230000012173 estrus Effects 0.000 description 7
- PBBGSZCBWVPOOL-UHFFFAOYSA-N hexestrol Chemical compound C=1C=C(O)C=CC=1C(CC)C(CC)C1=CC=C(O)C=C1 PBBGSZCBWVPOOL-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000027046 diestrus Effects 0.000 description 6
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 206010002659 Anovulatory cycle Diseases 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 231100000535 infertility Toxicity 0.000 description 5
- 201000005670 Anovulation Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 231100000552 anovulation Toxicity 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000029849 luteinization Effects 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 230000000624 ovulatory effect Effects 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 102000006771 Gonadotropins Human genes 0.000 description 3
- 108010086677 Gonadotropins Proteins 0.000 description 3
- 206010062662 Uterine mass Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 239000003687 estradiol congener Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000002622 gonadotropin Substances 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000035175 Oligomenorrhea Diseases 0.000 description 2
- 206010030295 Oligomenorrhoea Diseases 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 meso-3 Chemical compound 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001932 seasonal effect Effects 0.000 description 2
- 230000008142 sex development Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000011121 vaginal smear Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- KINNMTBWIQCDPS-UHFFFAOYSA-N 1,1,3-trimethyl-2-[3,7,12,16-tetramethyl-18-(2,2,6-trimethylcyclohexyl)octadecyl]cyclohexane Chemical class CC1CCCC(C)(C)C1CCC(C)CCCC(C)CCCCC(C)CCCC(C)CCC1C(C)CCCC1(C)C KINNMTBWIQCDPS-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 208000020848 Genetic infertility Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 206010036877 Prolonged Pregnancy Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 208000030373 chronic endometritis Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007778 menstrual function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000819 phase cycle Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 210000004911 serous fluid Anatomy 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1987/000065 WO1988009164A1 (en) | 1987-05-29 | 1987-05-29 | Pharmaceutical preparation having oestrogen action |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH672251A5 true CH672251A5 (enrdf_load_html_response) | 1989-11-15 |
Family
ID=21617114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH3458987A CH672251A5 (enrdf_load_html_response) | 1987-05-29 | 1987-05-29 |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPH02500362A (enrdf_load_html_response) |
| CH (1) | CH672251A5 (enrdf_load_html_response) |
| DE (1) | DE3790958T1 (enrdf_load_html_response) |
| FR (1) | FR2621485B1 (enrdf_load_html_response) |
| GB (1) | GB2213062B (enrdf_load_html_response) |
| WO (1) | WO1988009164A1 (enrdf_load_html_response) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004087179A1 (en) * | 2003-04-04 | 2004-10-14 | Indena S.P.A. | A process for the preparation of ferutinine from ferula genus plants |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2251249A1 (de) * | 1972-10-19 | 1974-05-02 | Hoechst Ag | Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten |
| CA1063935A (en) * | 1975-04-21 | 1979-10-09 | Frederick G. Wheeler | Antacid tablets and processes for their preparation |
| FR2481270A1 (fr) * | 1980-04-24 | 1981-10-30 | Roussel Uclaf | Nouveaux derives substitues de l'acide 4-phenyl 4-oxo 2-hydroxy butanoique, procede pour leur preparation et applications comme medicaments |
-
1987
- 1987-05-29 CH CH3458987A patent/CH672251A5/de not_active IP Right Cessation
- 1987-05-29 JP JP87505402A patent/JPH02500362A/ja active Pending
- 1987-05-29 WO PCT/SU1987/000065 patent/WO1988009164A1/ru active Application Filing
- 1987-05-29 DE DE19873790958 patent/DE3790958T1/de not_active Withdrawn
- 1987-10-07 FR FR8713841A patent/FR2621485B1/fr not_active Expired - Fee Related
-
1989
- 1989-01-26 GB GB8901641A patent/GB2213062B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004087179A1 (en) * | 2003-04-04 | 2004-10-14 | Indena S.P.A. | A process for the preparation of ferutinine from ferula genus plants |
| US7371886B2 (en) | 2003-04-04 | 2008-05-13 | Indena S.P.A. | Process for the preparation of ferutinine from Ferula genus plants |
| AU2004226853B2 (en) * | 2003-04-04 | 2009-06-04 | Indena S.P.A. | A process for the preparation of ferutinine from Ferula genus plants |
| US8101215B2 (en) | 2003-04-04 | 2012-01-24 | Indena S.P.A. | Process for cosmetic treatment using ferutinine from Ferula genus plants |
| US8247005B2 (en) | 2003-04-04 | 2012-08-21 | Indena S.P.A. | Process for cosmetic treatment using ferutinine from Ferula genus plants |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2213062B (en) | 1990-03-14 |
| GB2213062A (en) | 1989-08-09 |
| FR2621485A1 (fr) | 1989-04-14 |
| FR2621485B1 (fr) | 1990-02-16 |
| JPH02500362A (ja) | 1990-02-08 |
| DE3790958T1 (de) | 1989-05-24 |
| WO1988009164A1 (en) | 1988-12-01 |
| GB8901641D0 (en) | 1989-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Courrier | Interactions between estrogens and progesterone | |
| DE2746950C2 (enrdf_load_html_response) | ||
| DE2732175C2 (de) | Oxytocin-Strukturanaloga und diese Verbindungen enthaltende pharmazeutische Mittel | |
| DE60223795T2 (de) | Tetrahydroxyliertes Östrogen enthaltendes Arzneistoffverabreichungssystem zur Verwendung in der hormonalen Kontrazeption | |
| EP1474119A1 (de) | Verwendung von selektiv den estrogenrezeptor beta modulierenden phytoestrogenhaltigen extrakten | |
| Pal et al. | Flowers of Hibiscus rosa-sinensis, a potential source of contragestative agent: II. Possible mode of action with reference to anti-implantation effect of the benzene extract | |
| DE60103503T2 (de) | Verwendung von fsh zur behandlung von infertilität | |
| Dickens et al. | Observations upon the Preparation and Standardisation of the Ovarian Hormone | |
| DE2529523C2 (de) | Mittel zur Behandlung klimakterischer Ausfallerscheinungen | |
| Hartman et al. | THE EFFECT OF TESTOSTERONE ON THE MONKEY UTERUS AND THE ADMINISTRATION OF STEROIDAL HORMONES IN THE FORM OF DEANESLYPARKES PELLETS | |
| Pages et al. | Sabinyl acetate, the main component of Juniperus sabina L'Herit. essential oil, is responsible for antiimplantation effect | |
| CH672251A5 (enrdf_load_html_response) | ||
| Rydbero et al. | The effect of gonadotropic hormone treatment in cases of amenorrhoea: Production of true menstruation and increased excretion of oestrin | |
| EP0219447B1 (de) | Antigestagene zur Verschiebung der endometrialen Reifung | |
| Novak | AN APPRAISAL OF OVARIAN THERAPY. | |
| DE69434239T2 (de) | Verwendung eines Progesteronrezeptor-Antagonisten zur Verhütung oder Hemmung der Befruchtung | |
| Claus | Separation of anterior-lobe substances and study of their individual effects | |
| Waring | Effect of hormones on degeneration of the x-zone in the mouse adrenal | |
| Fields et al. | Enhancement of uterine cervix extensibility in oestrogen-primed mice following administration of relaxin | |
| Allen | The chemical and physiological properties, and clinical uses of the corpus luteum hormone, progesterone | |
| US11058737B2 (en) | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females | |
| Dahl-Iversen et al. | Cystic glandular hyperplasia of the endometrium elucidated by therapeutic experiences in patients and by experiments on rhesus monkeys | |
| Macht et al. | Effect of corpus luteum and ovarian extracts on the oestrus of the guinea pig | |
| Akook et al. | Study Effect of Pills and Alcoholic Extract of Rue Plant on the Histological Structure of Ovary in Adult Rabbit Females. | |
| Schoorl | Vitamin E research |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |